Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$5.47B
sum of reported positions
Reported positions
96
Changes vs prior quarter
77
21 new · 14 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 160 measured positions in 8 quarters, the typical new or larger position finished +0.2 pts against the S&P 500 and 51% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
| Company | Shares | Value | Weight |
|---|---|---|---|
STATE STR SPDR S&P 500 ETF TPUT | 950K | $709M | 13.0% |
| 4.17M | $513M | 9.4% | |
| 12.4M | $326M | 6.0% | |
| 7.07M | $204M |
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $3.92B | $5.47B |
| Positions | 89 | 96 |
| Biggest line | — | STATE STR SPDR S&P 500 ETF T 13% |
| 3.7% |
| 1.14M | $174M | 3.2% |
| 4.52M | $157M | 2.9% |
| 11.5M | $155M | 2.8% |
| 10.3M | $153M | 2.8% |
| 257K | $149M | 2.7% |
| 4.78M | $147M | 2.7% |
| 305K | $145M | 2.7% |
| 721K | $144M | 2.6% |
| 8.3M | $119M | 2.2% |
| 1.41M | $118M | 2.2% |
| 310K | $116M | 2.1% |
| 11.2M | $113M | 2.1% |
| 2.33M | $111M | 2.0% |
| 176K | $99M | 1.8% |
| 4.09M | $98.6M | 1.8% |
| 8.58M | $94.1M | 1.7% |
| 3.55M | $85.9M | 1.6% |
| 2.5M | $82.4M | 1.5% |
| 226K | $79.7M | 1.5% |
| 670K | $77.3M | 1.4% |
| 333K | $66.8M | 1.2% |
Avalyn Pharma (AVLN)
2.5M shares
Hut 8 (HUT)
670K shares
Amphenol (APH)
269K shares
ROUNDHILL ETF TRUST
603K shares
Cerebras Systems (CBRS)
172K shares
Dick's Sporting Goods (DKS)
151K shares
Broadcom (AVGO)
84K shares
Space Exploration Technologies (SPCX)
101K shares
Martin Marietta Materials (MLM)
26K shares
Planet Fitness (PLNT)
220K shares
Bloom Energy (BE)
34K shares
Kardigan (KARD)
400K shares
CVS Health (CVS)
85K shares
Centene Corporation (CNC)
99K shares
Celldex Therapeutics (CLDX)
121K shares
TRULIEVE CANNABIS CORP
356K shares
Lam Research (LRCX)
4,302 shares
Snowflake (SNOW)
5,600 shares
Alphabet (GOOGL)
3,400 shares
Charles River Laboratories (CRL)
1,010 shares
Inmed Pharmaceuticals (INM)
100K shares
